surgical impactor

Search documents
Zimmer Biomet (ZBH) FY Conference Transcript
2025-06-09 14:20
Zimmer Biomet (ZBH) FY Conference June 09, 2025 09:20 AM ET Speaker0 Okay. Good morning, everyone. We'll go ahead and get started here. Very pleased to welcome Ivan Tornos, Chairman and CEO of Zimmer Biomet and Sukhi Upade, Executive Vice President and CFO. As with all of these sessions, if you have a question, feel free to raise your hand. I certainly have have plenty to keep us to keep us going here, but obviously, we wanna keep this as interactive as possible. So why don't we start with with a topic that ...
Enovis(ENOV) - 2025 Q1 - Earnings Call Transcript
2025-05-08 13:32
Enovis (ENOV) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Kyle Rose - Vice President of Investor RelationsMatthew Trerotola - CEO & ChairmanBen Berry - CFOVijay Kumar - Senior Managing DirectorWilliam Plovanic - Managing Director - Equity ResearchDane Reinhardt - Senior Equity Research AssociateJoseph Conway - Equity Research AssociateRussell Yuen - Equity Research AssociateYoung Li - Senior VP - Equity Research Conference Call Participants Vik Chopra - AnalystRobert Marcus - Analyst ...
Enovis(ENOV) - 2025 Q1 - Earnings Call Transcript
2025-05-08 13:30
Enovis (ENOV) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Hello, everyone, and welcome to the Innovus Corporation Q1 twenty twenty five Results Call. My name is Ezra, and I will be your coordinator today. I will now hand you over to your host, Kyle Rose, Vice President of Investor Relations to begin. Please go ahead. Speaker1 Thank you, Ezra. Good morning, everyone, and thank you for joining us today for our first quarter twenty twenty five results conference call. I'm Kyle Rose, Vice President ...
Zimmer Biomet(ZBH) - 2025 Q1 - Earnings Call Transcript
2025-05-05 12:30
Zimmer Biomet (ZBH) Q1 2025 Earnings Call May 05, 2025 08:30 AM ET Company Participants David DeMartino - Senior VP of Investor RelationsIvan Tornos - President & CEOSuketu Upadhyay - Executive VP & CFODavid Roman - Managing DirectorTravis Steed - Managing Director - Equity ResearchChris Pasquale - Partner - Medical Devices & SuppliesMatt Taylor - Managing DirectorJoshua Jennings - Managing DirectorJoanne Wuensch. - Managing DirectorCaitlin Cronin - DirectorRichard Newitter - Managing Director Conference Ca ...
Zimmer Biomet(ZBH) - 2025 Q1 - Earnings Call Transcript
2025-05-05 12:30
Financial Data and Key Metrics Changes - In Q1 2025, Zimmer Biomet reported net sales of $1.909 billion, reflecting a 1.1% increase on a reported basis and a 2.3% increase excluding foreign currency impact [27] - Adjusted earnings per share (EPS) for the quarter was $1.81, down from $1.94 in the prior year, attributed to higher costs and investments [32] - The company generated $279 million in free cash flow, demonstrating robust growth compared to the previous year [26] Business Line Data and Key Metrics Changes - U.S. hips sales grew nearly 4%, while U.S. knees saw a modest growth of 0.2% [29] - The S.E.T. segment grew by 4.9%, with notable growth in CMFT and Sports categories [30] - International sales grew by 3.7%, driven by mid-single digit growth in knees and high-single digit growth in S.E.T. [28] Market Data and Key Metrics Changes - The U.S. market showed a 1.3% growth overall, with hips and S.E.T. driving performance [27] - Internationally, hips grew by 2.4%, with U.S. hips growing at 3.7% and international hips at 1% [29] - The company anticipates a full-year organic constant currency revenue growth of 3% to 5% for 2025 [10] Company Strategy and Development Direction - Zimmer Biomet is focusing on three strategic priorities: people and culture, operational excellence, and innovation and diversification [12] - The company aims to enhance its U.S. market performance through leadership changes and optimizing sales channels [14] - The recent acquisition of Paragon 28 is expected to contribute approximately 270 basis points to sales growth in 2025 [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the full-year guidance despite challenges such as tariffs and foreign exchange impacts [34] - The company is optimistic about new product launches and expects second-half growth to be higher than the first half due to favorable comparisons and new product uptake [35] - Management acknowledged the need for improved performance in the U.S. knee segment and is implementing strategies to enhance competitiveness [81] Other Important Information - The company reported a reduction in days on hand inventory from over 400 days in early 2024 to approximately 370 days [15] - The Paragon 28 acquisition was successfully integrated with minimal disruption, retaining key leadership and sales teams [110] Q&A Session Summary Question: Impact of tariffs on EPS and mitigation efforts - Management detailed steps taken to mitigate tariff impacts, including optimizing country of origin and sourcing adjustments, expecting a $60 million to $80 million headwind for 2025 [45][46] Question: Growth expectations and new product impacts - Management indicated confidence in achieving mid-single digit growth in the second half of 2025, driven by new product launches and improved execution [56][57] Question: Performance in ASC versus hospital channels - The company noted that over 20% of U.S. sales now come from the ASC environment, with expectations for continued growth in this area [94] Question: Pricing trends and future expectations - Management expects pricing to remain flat for 2025, with a stable environment compared to historical norms, despite previous fluctuations [68][69] Question: Clarification on the Paragon acquisition integration - The integration of Paragon 28 is progressing well, with all key personnel retained and ongoing product innovations maintained [110]